The work addresses a central limitation of conventional polygenic risk scores. These scores summarize the combined influence of many genetic variants associated with a particular condition, usually by comparing affected individuals with unaffected controls. A high schizophrenia polygenic risk score can indicate increased genetic liability for schizophrenia, but it does not automatically reveal whether that liability is more specific to schizophrenia than to bipolar disorder or major depressive disorder. Psychiatric conditions share thousands of genetic associations, and the same variant can contribute to vulnerability across multiple disorders. As a result, a score developed for one diagnosis may be informative but not necessarily diagnostically discriminating. DDx-PRS was created to use this overlap as information rather than treating it as noise.

The method works by combining several genetic risk scores with the relationships among them. Those relationships are represented through a variance–covariance structure, a statistical description of how genetic liabilities for different disorders vary together. If genetic risk for schizophrenia and bipolar disorder is strongly correlated, the model accounts for that shared component while also evaluating the residual pattern that may distinguish one disorder from the other. In practical terms, DDx-PRS does not simply add up a person’s risk scores independently. It asks which diagnostic category best fits the entire multivariate genetic profile, given how those profiles behave across large populations. The model also incorporates prior clinical probabilities, meaning the estimated prevalence or expected frequency of each diagnostic category in the setting where the tool is used.

This Bayesian element is critical. A probability estimate is not determined by genetics alone; it also depends on the starting probability of each outcome. In a specialist psychiatric clinic, the prior probability of schizophrenia, bipolar disorder or major depressive disorder may differ substantially from that in the general population. DDx-PRS updates those starting probabilities using an individual’s genetic profile, producing posterior probabilities for each category. The result is therefore not a simple label and should not be interpreted as a genetic diagnosis. Rather, it is a calibrated estimate of how the available genetic evidence shifts the odds among competing possibilities. The model’s output could be especially useful when a patient presents with overlapping symptoms, an unclear illness trajectory or a family history involving multiple psychiatric conditions.

To test the approach, the researchers used data assembled by the Psychiatric Genomics Consortium, one of the largest international collaborations in psychiatric genetics. The training analyses drew on summary-level results from three large case–control genome-wide association studies covering schizophrenia, bipolar disorder and major depressive disorder. Across these studies, the numbers of cases ranged from 41,917 to 173,140, while the combined sample included 1,048,683 individuals. Genome-wide association studies scan the genome for variants that occur more frequently in people with a condition than in comparison groups. By using summary-level data rather than requiring access to each participant’s full genetic dataset, the researchers could estimate the cross-disorder genetic architecture while preserving a practical degree of data separation.

The model was then evaluated in held-out test data from different cohorts, a design intended to provide a more demanding assessment than testing on the same individuals used for development. The test sample contained 11,460 participants, with equal numbers representing schizophrenia, bipolar disorder, major depressive disorder and controls. Equal representation makes it easier to compare classification performance across categories, although it does not reproduce the prevalence of these conditions in the general population. The researchers also examined calibration, which measures whether predicted probabilities correspond to observed frequencies. If a group of people is assigned a 50% probability of schizophrenia, a well-calibrated method should find that approximately half of them actually belong to that category under the study definition. Calibration is essential for clinical interpretation because a highly discriminative score can still be misleading if its probabilities are systematically exaggerated or understated.

According to the study, DDx-PRS was well calibrated and showed statistical power consistent with simulation results. It also produced results comparable to alternative methods that require tuning data. Tuning typically involves using an additional dataset to decide how different predictors should be weighted or how classification thresholds should be set. Avoiding that requirement could make DDx-PRS more adaptable when independent tuning cohorts are unavailable, a common problem in psychiatric genetics and in populations that are historically underrepresented in research. The method’s performance reflects the fact that it models the covariance between disorders directly, allowing shared genetic liability to be separated from patterns that are relatively more characteristic of one diagnostic category.

One of the most striking findings emerged when the investigators examined people in the highest deciles of predicted diagnostic probability. Within these top-ranked groups, the proportion of individuals with the corresponding true diagnosis was considerably higher than the prior baseline probability. In other words, the method could enrich a population for people more likely to have a particular disorder, even though it could not provide certainty for any single individual. This distinction matters. A tool that increases the concentration of likely cases may have value for research recruitment, risk stratification, screening in carefully defined settings or prioritizing further clinical assessment. It does not mean that genetic probabilities can replace interviews, longitudinal observation, medical evaluation or professional judgment.

The potential clinical significance of DDx-PRS lies partly in the instability of psychiatric diagnoses over time. Symptoms such as depression, psychosis, impulsivity, sleep disruption and cognitive changes can occur in more than one disorder, while the full clinical picture may emerge only after months or years. Early treatment decisions can nevertheless have lasting consequences, and medications that are helpful for one condition may be less appropriate or carry particular risks in another. A probabilistic genetic profile could eventually contribute one piece of evidence to a broader diagnostic process, especially when symptoms are mixed or family histories are complex. However, the current findings do not establish that using DDx-PRS improves patient outcomes, changes treatment decisions safely or performs equally well across ancestries, healthcare systems and real-world clinical populations.

Important challenges remain before such a method could be considered for routine care. Polygenic scores are influenced by the ancestry composition of the datasets used to develop them, and prediction accuracy can decline when a model is transferred to populations that were poorly represented in the original studies. Diagnostic categories themselves are also imperfect biological entities, with substantial heterogeneity within each label. A person diagnosed with major depressive disorder may have a very different genetic and clinical profile from another person carrying the same diagnosis. In addition, prior probabilities must be selected carefully: applying a model calibrated in one population to another setting without adjustment could produce distorted posterior estimates. Privacy, informed consent, genetic counseling and the possibility of stigma would also need to be addressed.

The researchers present DDx-PRS as a framework for distinguishing related disorders, not as a replacement for psychiatric expertise. Its main advance is conceptual as much as technical: it treats diagnosis as a competition among plausible categories and calculates how a person’s multivariate genetic evidence changes the probability of each one. As genetic studies grow larger and become more diverse, the underlying covariance estimates may become more precise, potentially improving discrimination between overlapping disorders. For now, the study offers an important proof of principle. Genetic data may be most informative in psychiatry not when they are used to declare a single diagnosis, but when they are integrated probabilistically to clarify a difficult differential diagnosis and identify where additional clinical evidence is most urgently needed.

Subject of Research: A polygenic method for distinguishing among schizophrenia, bipolar disorder, major depressive disorder and control categories using shared and disorder-specific genetic risk.

Article Title: Distinguishing different psychiatric disorders using DDx-PRS

Article References: Peyrot, W.J., Panagiotaropoulou, G., Olde Loohuis, L.M. et al. Distinguishing different psychiatric disorders using DDx-PRS. Nature Genetics (2026). https://doi.org/10.1038/s41588-026-02684-x

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41588-026-02684-x

Keywords: DDx-PRS, polygenic risk score, psychiatric genetics, schizophrenia, bipolar disorder, major depressive disorder, differential diagnosis, genome-wide association study, precision psychiatry, psychiatric disorders

The methodology centered around Local Analysis of (Co)variant Association (LAVA), which partitions the genome and evaluates genetic correlations (r_g) within each block. This approach transcends traditional genome-wide methods that average genetic overlap and potentially obscure important regional variation. By imposing stringent heritability thresholds and multiple-testing corrections, the study identified 458 statistically significant pairwise local genetic correlations between disorder pairs. The vast majority of these r_g estimates were positive, reinforcing the notion that increased genetic risk for one psychiatric condition typically heightens vulnerability for others—a key insight into the intertwined nature of mental illness etiology.

Prominent among disorder pairs with the largest numbers of significant local correlations were Major Depression (MD) with Anxiety Disorders (ANX), MD with Post-Traumatic Stress Disorder (PTSD), and Bipolar Disorder (BIP) with Schizophrenia (SCZ). These findings harmonize with broader genetic overlap indicated by genome-wide linkage disequilibrium score regression (LDSC) and polygenic overlap analyses, underscoring consistent genetic pathways shared across major psychiatric phenotypes. The discovery of both global and local r_g landscapes illustrates a pervasive positive genetic interconnection, with very few instances of negative correlations, highlighting the complex but cooperative genetic interplay shaping mental health disorders.

Of particular note, the researchers identified 101 genomic “hotspots”—regions exhibiting significant pleiotropic genetic correlations across multiple psychiatric disorders. The most remarkable hotspot resides on chromosome 11, spanning base pairs 112,755,447 to 114,742,317. This locus displayed 17 significant and positive local r_g associations involving eight of the fourteen disorders studied, making it a nexus of genetic risk. This chromosomal segment also featured among the top loci associated with the majority of these disorder pairs, suggesting a critical hub of genetic influence.

This region on chromosome 11 encompasses the well-studied NCAM1–TTC12–ANKK1–DRD2 gene cluster, a genetic constellation repeatedly implicated in various psychiatric and behavioral phenotypes. Previous research has connected variants in this cluster to neuropsychiatric conditions including Attention Deficit Hyperactivity Disorder (ADHD), nicotine dependence, and suicidal behavior. The current findings reinforce and expand the significance of this locus, positioning it as a central player in the shared genetic architecture underlying diverse psychiatric disorders.

By leveraging the LAVA framework within finely partitioned LD segments, the study affords unparalleled resolution in detecting not only significant genetic correlations but also their spatial clustering across the genome. This local r_g mapping enriches our understanding of pleiotropy, illuminating genetic hotspots where pathogenic effects may converge. Such insights could catalyze precision medicine strategies, enabling targeted research on these key genomic regions to decipher mechanistic pathways and inform therapeutic interventions.

Contrasting with the dominance of positive genetic correlations, only three instances of significant negative local r_g were detected. This scarcity suggests that, in most cases, genetic factors conferring risk to one psychiatric disorder do not simultaneously protect against another, but rather promote comorbidity or symptom overlap. This revelation challenges simplistic models of psychiatric genetics and highlights the necessity for nuanced exploration of individual genetic variants’ pleiotropic effects.

The study’s integration of genome-wide estimates, local correlation analyses, and network modeling depicts a complex, interconnected psychiatric genomic landscape. Disorders sharing a factor structure in genomic structural equation modeling also tend to cluster geographically within the local r_g network plots, reflecting biologically meaningful relationships. This concordance bolsters confidence in the multi-layered analytic strategy and encourages application of similar frameworks in future psychiatric genetics research.

Moreover, the delineation of disorder-specific and pleiotropic loci invites reevaluation of current nosological boundaries. Genetic hotspots implicating multiple disorders suggest shared etiological underpinnings, potentially informing revised classifications reflective of underlying biology rather than purely clinical symptomatology. Such a shift could transform diagnostic practices and facilitate cross-disorder therapeutic development.

This research advances the frontier of psychiatric genetics by precisely mapping where and how genetic risk overlaps across numerous mental health conditions within the human genome. The identification of robust, highly pleiotropic regions like the chromosome 11 locus provides fertile ground for functional follow-up studies. Understanding the behavior of genes within these hotspots may unlock critical pathways mediating broad psychiatric vulnerability, ultimately guiding novel intervention strategies.

The implications extend beyond psychiatry, as pleiotropy hotspots often harbor genes influencing cognitive traits, personality dimensions, substance use, and sleep patterns. This multidimensional genetic interrelation underscores the complexity of brain function and its susceptibility to diverse perturbations. Future endeavors integrating genomic data with transcriptomic and epigenomic profiles promise to elucidate the mechanistic cascades linking genotype to psychiatric phenotype.

This study exemplifies the power of integrating rigorous statistical genetics with biomedically informed genomic segmentation to disentangle the polygenic architecture of complex psychiatric traits. By moving beyond global averages to local genetic landscapes, the authors highlight the heterogeneity and specificity inherent in psychiatric genetic risk, advancing both conceptual frameworks and practical methodologies.

Collectively, these findings reshape our understanding of psychiatric disorder genetics, revealing a mosaic of interconnected genetic influences spread variably across the genome. The elucidation of local r_g hotspots offers a roadmap to targeted gene discovery and functional validation. As genetic research marches forward, such finely resolved maps are indispensable for translating genomic knowledge into clinical precision psychiatry.

In summation, this pioneering investigation maps the intricate web of local genetic correlations that knit together the genetic risk profiles of a broad spectrum of psychiatric disorders. Identifying both shared genetic burdens and disorder-specific components will pave the way for a more integrated and biologically grounded classification of mental health conditions, fostering advances across diagnosis, treatment, and prevention in psychiatric medicine.

Subject of Research: Mapping the local genetic correlations and pleiotropy across 14 psychiatric disorders.

Article Title: Mapping the genetic landscape across 14 psychiatric disorders.

Article References:
Grotzinger, A.D., Werme, J., Peyrot, W.J. et al. Mapping the genetic landscape across 14 psychiatric disorders. Nature (2025). https://doi.org/10.1038/s41586-025-09820-3

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41586-025-09820-3